Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unlicensed by the MHRA or EMA and still being evaluated in Phase 2 and Phase 3 clinical trials
Patients assigned bimagrumab in the clinical trial received IV infusions of the drug at weeks 4, 16, 28 and 40
If you want clarity on a specific lab value or testing scenario, bring the result, your dose timeline, and a brief symptom log to your clinician
Laboratory research record on GLP-1S [PMID: 37203328] PubMed laboratory record discussing GLP-1S in a research context
US$ 20.02
US$ 21.38
.png)
US$ 25.84
US$ 28.68
US$ 20.65
